| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-16 13:00:00 |
Czytaj oryginał (ang.) |
| Securities Investigation: Levi & Korsinsky Investigates Capricor Therapeutics, Inc. (CAPR) on Behalf of Investors |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA. |
accessnewswire.com |
2025-05-14 14:45:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-14 13:00:00 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Conference Call Transcript |
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Officer Conference Call Participants Ed Tenthoff - Piper Sandler Leland Gershell - Oppenheimer Kristen Kluska - Cantor Fitzgerald Catherine Novack - Jones Research Aydin Huseynov - Ladenburg Maanasa Sangeetha - Roth Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics First Quarter 2025 Earnings Call. |
seekingalpha.com |
2025-05-14 00:36:33 |
Czytaj oryginał (ang.) |
| CAPR STOCK ALERT: Levi & Korsinsky Notifies Capricor Therapeutics, Inc. Investors of an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA. |
accessnewswire.com |
2025-05-13 16:25:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Capricor Therapeutics, Inc. Investors of the Ongoing Investigation Into Potential Violations of Securities Laws - CAPR |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA. |
accessnewswire.com |
2025-05-12 21:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR |
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-05-12 21:07:00 |
Czytaj oryginał (ang.) |
| ATTENTION CAPR SHAREHOLDERS: Investors Who Lost Money on Capricor Therapeutics, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA. |
accessnewswire.com |
2025-05-12 11:30:00 |
Czytaj oryginał (ang.) |
| CAPR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Capricor Therapeutics, Inc. |
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA. |
accessnewswire.com |
2025-05-10 22:01:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR |
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-10 12:00:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Capricor Therapeutics, Inc. (CAPR) should contact Levi & Korsinsky about Securities Fraud Investigation - CAPR |
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA. |
accessnewswire.com |
2025-05-09 15:15:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR |
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-09 14:53:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Investigates Possible Securities Fraud Violations by Capricor Therapeutics, Inc. (CAPR) |
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning possible violations of federal securities laws. Capricor issued a press release on May 5, 2025, announcing that after "the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy", the FDA had "confirmed its intent to hold an advisory committee meeting" in connection with the BLA. |
accessnewswire.com |
2025-05-08 16:45:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR |
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR |
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-07 17:15:00 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 |
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. |
globenewswire.com |
2025-05-06 13:15:00 |
Czytaj oryginał (ang.) |
| US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy |
Capricor Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) plans to convene a panel of outside experts before deciding on the company's cell therapy for a heart condition related to Duchenne muscular dystrophy (DMD). |
reuters.com |
2025-05-05 15:08:14 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy |
-Company remains on track for PDUFA target action date of August 31, 2025- -Advisory committee meeting to be held in advance of target action date- SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. During the meeting, FDA stated that no significant deficiencies have been identified by the Review Committee and that the package is on track for a Prescription Drug User Fee Act (PDUFA) action date of August 31, 2025. |
globenewswire.com |
2025-05-05 12:00:00 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript |
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marban - Chief Executive Officer Conference Call Participants Edward Tenthoff - Piper Sandler Leland Gershell - Oppenheimer Joseph Pantginis - H.C. |
seekingalpha.com |
2025-03-19 20:56:53 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates |
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.02 per share a year ago. |
zacks.com |
2025-03-19 20:15:20 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data |
Capricor Therapeutics has filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD cardiomyopathy, with strong FDA recognition. Deramiocel's efficacy was demonstrated in the HOPE-2 trials, with significant improvements in PUL 1.2 scores and positive long-term benefits in PUL 2.0 and LVEF measures. Financially, Capricor is well-positioned with a strong cash runway, strategic partnerships, and projected significant revenue from deramiocel sales by 2030. |
seekingalpha.com |
2025-02-23 23:13:43 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade |
The consensus price target hints at a 208.1% upside potential for Capricor (CAPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-01-16 13:01:30 |
Czytaj oryginał (ang.) |
| CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA |
Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States. |
zacks.com |
2025-01-03 13:35:35 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy |
-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. “The submission of the BLA marks a pivotal step for Capricor and those impacted by DMD. |
globenewswire.com |
2025-01-02 11:15:00 |
Czytaj oryginał (ang.) |
| Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached |
Capricor Therapeutics is advancing deramiocel, an allogeneic cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Deramiocel showed significant improvements in upper limb function and LVEF in Phase 2 trials, with ongoing open-label extension trials supporting long-term efficacy and safety. Despite promising prospects, Capricor's upside is limited due to prior commercialization deals, but the stock remains attractively valued with potential milestone payments and royalties. |
seekingalpha.com |
2024-12-07 07:08:41 |
Czytaj oryginał (ang.) |
| Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission |
Capricor Therapeutics initiated its rolling BLA submission for Deramiocel to treat Duchenne Muscular Dystrophy Cardiomyopathy, with completion expected before the end of 2024. The company presented promising 3-year data from the HOPE-2 OLE study, showing significant improvements in cardiac and skeletal muscle functions. Capricor raised $86.3 million in a public offering, ensuring sufficient cash runway to fund operations into 2027, excluding potential milestone payments from Nippon Shinyaku. |
seekingalpha.com |
2024-12-06 10:00:00 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics to Present at Upcoming Investor Conferences |
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at the following upcoming investor conferences. |
globenewswire.com |
2024-12-02 18:15:00 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript |
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Officer Conference Call Participants Ted Tenthoff - Piper Sandler Leland Gershell - Oppenheimer Rick Miller - Cantor Fitzgerald Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen and welcome to the Capricor's Third Quarter 2024 Financial Results and Corporate Update Call. |
seekingalpha.com |
2024-11-14 01:12:09 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates |
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.25 per share a year ago. |
zacks.com |
2024-11-13 20:11:12 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the third quarter ended September 30, 2024 and provided a corporate update. |
globenewswire.com |
2024-11-13 18:01:00 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in Capricor (CAPR) Should Keep going |
Capricor (CAPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2024-11-11 11:51:17 |
Czytaj oryginał (ang.) |
| Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year? |
Here is how Capricor Therapeutics (CAPR) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year. |
zacks.com |
2024-11-07 12:40:20 |
Czytaj oryginał (ang.) |
| Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline |
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-11-05 13:05:46 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares |
SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today the closing of its previously announced underwritten public offering of 5,073,800 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares to cover over allotments, bringing the total gross proceeds to Capricor from the offering to approximately $86.3 million, before deducting underwriting commissions and other offering expenses payable by Capricor. All of the shares of common stock sold in the offering, including the over-allotment, were offered by Capricor. The closing of the offering occurred on October 18, 2024. |
globenewswire.com |
2024-10-18 20:01:00 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock |
SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the pricing of its underwritten offering of 4,412,000 shares of common stock at a public offering price of $17.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 661,800 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on October 18, 2024, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2024-10-17 10:00:00 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics Announces Proposed Public Offering of Common Stock |
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2024-10-16 20:17:00 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress |
-Data Supports Deramiocel's Sustained Efficacy and Safety in Treating DMD- -Improvements Seen in Multiple Cardiac and Skeletal Endpoints Demonstrating Stabilization of Cardiac and Skeletal Muscle Function Over 3 Years of Treatment- -Company on Track to Fully Submit Biologics License Application (BLA) by End of 2024- SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive 3-year safety and efficacy results from its ongoing HOPE-2 open label extension (OLE) study for its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). The data was highlighted in a late-breaking poster presentation at the 29th Annual Congress of the World Muscle Society (WMS), October 8-12, 2024 in Prague, Czechia. |
globenewswire.com |
2024-10-11 13:15:00 |
Czytaj oryginał (ang.) |
| What Makes Capricor (CAPR) a Good Fit for 'Trend Investing' |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Capricor (CAPR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2024-10-09 13:50:35 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy |
-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA- |
globenewswire.com |
2024-10-09 13:15:00 |
Czytaj oryginał (ang.) |
| Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect? |
The mean of analysts' price targets for Capricor (CAPR) points to a 90.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-10-08 14:55:30 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress |
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today that the Company will present the three-year safety and efficacy results from its HOPE-2 open-label extension (OLE) study with lead asset deramiocel for treating Duchenne muscular dystrophy (DMD). The data will highlight the long-term, multi-modal benefits of deramiocel in a late-breaking poster presentation at the 29th Annual Congress of the World Muscle Society (WMS 2024), taking place October 8-12, 2024, in Prague, Czechia. |
globenewswire.com |
2024-10-04 13:15:00 |
Czytaj oryginał (ang.) |
| Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher |
Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year. |
benzinga.com |
2024-10-01 18:08:45 |
Czytaj oryginał (ang.) |